Boston Scientific (BSX) Capital Expenditures (2009 - 2026)

Boston Scientific has disclosed Capital Expenditures across 18 years of filings, most recently posting $195.0 million for Q2 2026.

• In Q2 2026, Capital Expenditures rose 24.2% year-over-year to $195.0 million; the TTM figure through Jun 2026 stood at $904.0 million (up 13.0% YoY), while the FY2025 annual figure was $876.0 million, up 10.89% from the prior year.
• Capital Expenditures came in at $195.0 million for Q2 2026 at Boston Scientific, up from $177.0 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $351.0 million in Q4 2025 to a low of $105.0 million in Q2 2022.
• Average Capital Expenditures over 5 years is $185.4 million, with a median of $179.0 million recorded in 2024.
• The largest YoY upside for Capital Expenditures was 61.33% in 2022 against a maximum downside of 20.3% in 2022.
• Over 5 years, Capital Expenditures stood at $212.0 million in 2022, then gained by 25.94% to $267.0 million in 2023, then advanced by 3.75% to $277.0 million in 2024, then climbed by 26.71% to $351.0 million in 2025, then tumbled by 44.44% to $195.0 million in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $195.0 million in Q2 2026, $177.0 million in Q1 2026, and $351.0 million in Q4 2025.